FLT3 and prostate carcinoma: Even though pexidartinib was reported to function through targets other than CSF-1R, such as cKIT, FMS-like tyrosine kinase 3 (FLT3), and platelet-derived growth factor receptors β (PDGFR-β), no observable differences were found in our previous study when pexidartinib was used alone in a prostate cancer xenograft mouse model [4].